Evolution of <i>AR</i> and Non- <i>AR</i> Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
AR alterations in ctDNA accumulate at progression in mCRPC patients treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer.
Authors
- YINGMING LI
- Anna Kobilka
- Charles J. Ryan (ORCID: https://orcid.org/0000-0002-2081-3557)
- Siyuan Guo (ORCID: https://orcid.org/0000-0002-4372-9040)
- Todd P. Knutson
- Chenxi Yu (ORCID: https://orcid.org/0000-0002-2813-9528)
- Bin Luo (ORCID: https://orcid.org/0000-0002-3983-5676)
- Luke Gaughan
- Scott M. Dehm (ORCID: https://orcid.org/0000-0002-7827-5579)
- José C. Valentín López
- Susan Halabi
- Sarah A. Munro
- Andrew J. Armstrong
- Emmanuel S. Antonarakis
- Rakesh Heer
- Jacqueline Lyman
- Michael J. Morris
Institutions
- University of Minnesota (US)
- Memorial Sloan Kettering Cancer Center (US)
- Duke University (US)
- University of Minnesota System (US)
- Cancer Research UK (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Dana-Farber Cancer Institute (US)
- Duke Medical Center (US)
- University of Minnesota Medical Center (US)
- Minnesota Oncology (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2779
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- U.S. Department of Health and Human Services
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Celgene
- University of Minnesota
- Movember Foundation
- MacroGenics
- Astellas Pharma
- National Institutes of Health
- U.S. Army
- National Cancer Institute